Omega Therapeutics
OMGA

$1.37

3.52%

Market Cap: $75.6M

About: Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.

Employees: 94

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

31% more call options, than puts

Call options by funds: $94K | Put options by funds: $72K

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

1.37% less ownership

Funds ownership: 92.97% [Q1] → 91.61% (-1.37%) [Q2]

6% less funds holding

Funds holding: 70 [Q1] → 66 (-4) [Q2]

17% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 23

43% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 21

44% less capital invested

Capital invested by funds: $187M [Q1] → $105M (-$82.5M) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

338%

upside

Avg. target

$10

630%

upside

High target

$12

776%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Robert Burns 45% 1-year accuracy 69 / 154 met price target	776%upside $12	Buy Reiterated	15 Aug 2024
Wedbush Robert Driscoll 56% 1-year accuracy 38 / 68 met price target	776%upside $12	Outperform Reiterated	7 Aug 2024
Chardan Capital Keay Nakae 38% 1-year accuracy 21 / 56 met price target	338%upside $6	Buy Maintained	7 Aug 2024

See Analyst Rankings

Financial journalist opinion

Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications

CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the publication of preclinical data from studies of OTX-2002 in Nature Communications. The article highlights the potential of Omega's approach to precision epigenomic control and the ability of OTX-2002 to controllably regulate the historically undruggable MYC gene in multiple models of hepatocellular carcinoma (HCC), the most common type of primary liver cancer.

Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications

Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research

CAMBRIDGE, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the addition of Jennifer Nelson, Ph.D., to the Company's executive leadership team in the role of Senior Vice President of Research. She brings over 20 years of experience working with RNA- and DNA-based therapies and technologies, and extensive expertise as a leader in building novel platforms.

Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research

Zacks Investment Research

Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates

Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago.

Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates

Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent Company progress.

Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors

Former Merck veteran brings extensive expertise across corporate finance, business development and corporate licensing Former Merck veteran brings extensive expertise across corporate finance, business development and corporate licensing

Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors

Omega Therapeutics To Participate In Two Upcoming Investor Conferences

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in fireside chats at two upcoming investor conferences.

Omega Therapeutics To Participate In Two Upcoming Investor Conferences

Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer

CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Kaan Certel, Ph.D., as Chief Business Officer. Dr. Certel brings to Omega extensive biopharmaceutical industry experience and will be responsible for global business development activities including strategic partnerships.

Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer

Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the presentation of new preclinical data demonstrating durable and tunable bidirectional regulation of gene expression in cellular models at the pre-transcriptional level at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, taking place in Baltimore, Maryland, May 7 – 11.

Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers

Zacks Investment Research

Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates

Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.50 per share a year ago.

Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates

Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent Company progress.

Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

See News Rankings